Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Silverman

Showing results (791-800 of 846) with videos related to

Pageof 85
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|November 2, 2004
Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young menA R van Troostenburg, E V Clark, W D H Carey, et al.
Plos Pathogens|April 13, 2006
Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variantAnatoly Urisman, Ross J Molinaro, Nicole Fischer, et al.
Journal of Eating Disorders|January 4, 2026
An open-label pilot study of psilocybin-assisted therapy for binge eating disorderJesse Dallery, Jennifer L Miller, Jeff Boissoneault, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibodyG A Wiseman, C A White, T E Witzig, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2012
The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small moleculeBenedict C S Cross, Peter J Bond, Pawel G Sadowski, et al.
The Journal of Antimicrobial Chemotherapy|September 6, 2020
A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjectsKevin W Garey, Khurshida Begum, Chris Lancaster, et al.
Nature Genetics|November 5, 2002
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer casesGraham Casey, Phillippa J Neville, Sarah J Plummer, et al.
Frontiers in Neurology|April 9, 2013
Computer-Aided Diagnosis and Localization of Lateralized Temporal Lobe Epilepsy Using Interictal FDG-PETWesley T Kerr, Stefan T Nguyen, Andrew Y Cho, et al.
Alimentary Pharmacology & Therapeutics|October 21, 2021
Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitisRifaat Safadi, Marius Braun, Adi Francis, et al.
The Oncologist|January 10, 2013
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation studySalomon M Stemmer, Ofer Benjaminov, Gal Medalia, et al.
Pageof 85

Showing results (791-800 of 846) with videos related to

Sort By:
Pageof 85
International Journal of Clinical Pharmacology and Therapeutics|November 2, 2004
Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young menA R van Troostenburg, E V Clark, W D H Carey, et al.
Plos Pathogens|April 13, 2006
Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variantAnatoly Urisman, Ross J Molinaro, Nicole Fischer, et al.
Journal of Eating Disorders|January 4, 2026
An open-label pilot study of psilocybin-assisted therapy for binge eating disorderJesse Dallery, Jennifer L Miller, Jeff Boissoneault, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibodyG A Wiseman, C A White, T E Witzig, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2012
The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small moleculeBenedict C S Cross, Peter J Bond, Pawel G Sadowski, et al.
The Journal of Antimicrobial Chemotherapy|September 6, 2020
A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjectsKevin W Garey, Khurshida Begum, Chris Lancaster, et al.
Nature Genetics|November 5, 2002
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer casesGraham Casey, Phillippa J Neville, Sarah J Plummer, et al.
Frontiers in Neurology|April 9, 2013
Computer-Aided Diagnosis and Localization of Lateralized Temporal Lobe Epilepsy Using Interictal FDG-PETWesley T Kerr, Stefan T Nguyen, Andrew Y Cho, et al.
Alimentary Pharmacology & Therapeutics|October 21, 2021
Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitisRifaat Safadi, Marius Braun, Adi Francis, et al.
The Oncologist|January 10, 2013
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation studySalomon M Stemmer, Ofer Benjaminov, Gal Medalia, et al.
Pageof 85